Gaissert Henning A, Roper Charles L, Patterson G Alexander, Grillo Hermes C
Thoracic Surgical Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
Ann Thorac Surg. 2003 Feb;75(2):342-7. doi: 10.1016/s0003-4975(02)04343-6.
Immunodeficiency predisposes to invasive esophageal infections. The treatment of perforation, respiratory fistula, and necrosis due to transmural esophageal infection is guided by anecdote. We wish to determine treatment and outcome of local complications of necrotizing esophagitis.
We report our experience over a 7-year period and review published reports since 1976. We treated 4 patients and found 21 reported patients with perforation (11/25), fistula (8/25), and necrosis (6/25) at a mean age of 35 years. Twenty-one patients were immunodeficient (84%) due to acquired immunodeficiency syndrome in 8, acute leukemia in 6, renal transplant in 3, diabetes mellitus, renal failure, and corticosteroids in 1 each. Pathogenic organisms were fungal in 15 cases, viral in 7, and bacterial in 7.
Treatment consisted of antibiotic therapy in 13 patients and surgical intervention combined with antibiotic therapy in 12: esophagectomy in 6, esophageal stenting and drainage in 2, drainage alone in 2, and salivary diversion in 2. Overall mortality was 48% (12/25). Mortality without surgical intervention was 90% (9/10) and with surgical intervention 27% (3/11). One of 6 patients undergoing esophagectomy (17%) died. The difference in mortality was due to sepsis, which was the cause of death in 8 patients treated with medical intervention and only 1 treated with surgical intervention.
Local complications of necrotizing esophagitis have a high mortality due to sepsis. Surgical intervention, in particular esophagectomy, controls sepsis in published case reports and should be considered in selected patients. Further study is required to determine the true prevalence of these complications and the outcome of intervention.
免疫缺陷易引发食管侵袭性感染。对于因透壁性食管感染导致的穿孔、呼吸瘘和坏死的治疗,目前尚无明确的指导依据,多基于个案经验。我们旨在确定坏死性食管炎局部并发症的治疗方法及预后情况。
我们报告了7年间的经验,并回顾了自1976年以来发表的相关报告。我们共治疗了4例患者,并发现有21例已报道的患者出现穿孔(11/25)、瘘管(8/25)和坏死(6/25),平均年龄为35岁。21例患者(84%)存在免疫缺陷,其中8例因获得性免疫缺陷综合征,6例因急性白血病,3例因肾移植,1例分别因糖尿病、肾衰竭和使用皮质类固醇药物。致病微生物中,真菌15例,病毒7例,细菌7例。
13例患者接受了抗生素治疗,12例患者接受了手术干预并联合抗生素治疗:6例行食管切除术,2例行食管支架置入及引流术,2例仅行引流术,2例进行唾液改道术。总体死亡率为48%(12/25)。未接受手术干预的患者死亡率为90%(9/10),接受手术干预的患者死亡率为27%(3/11)。6例行食管切除术的患者中有1例(17%)死亡。死亡率的差异归因于脓毒症,在接受药物治疗的8例患者中,脓毒症是导致死亡的原因,而在接受手术治疗的患者中,仅有1例因脓毒症死亡。
坏死性食管炎的局部并发症因脓毒症导致的死亡率较高。在已发表的病例报告中,手术干预,尤其是食管切除术,可控制脓毒症,对于部分患者应考虑采用。需要进一步研究以确定这些并发症的真实患病率及干预效果。